查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1927397

標靶基因組分析試劑盒市場（依標靶類型、產品類型、應用領域及最終用戶分類）－2026-2032年全球預測

Targeted Genome Analysis Kits Market by Target Type, Product Type, Application Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，標靶基因組分析試劑盒市場價值將達到 28.9 億美元，到 2026 年將成長至 30.6 億美元，到 2032 年將達到 44.8 億美元，年複合成長率為 6.46%。

關鍵市場統計數據
基準年 2025 28.9億美元
預計年份：2026年 30.6億美元
預測年份 2032 44.8億美元
複合年成長率 (%) 6.46%

本文簡要概述了技術進步、臨床應用和供應趨勢如何改變標靶基因組分析試劑盒的決策過程。

標靶基因組分析試劑盒已從小眾研究工具發展成為轉化科學、臨床診斷和生物製藥開發的基礎組成部分。檢測化學、儀器通量和生物資訊學解讀技術的進步，共同拓展了定序、qPCR、微陣列和雜合反應平台的效用，使實驗室能夠以更高的精度和操作效率研究基因變異和表現。因此，採購團隊、研發負責人和診斷試劑開發人員越來越關注試劑盒的性能特徵，例如靈敏度、特異性、工作流程整合性和供應可靠性。

分析技術、物流和監管因素的融合，這些因素正在推動標靶基因組分析試劑盒的開發、採購和部署方式的快速變化。

由於儀器技術、試劑化學和數據分析的同步發展，標靶基因組分析試劑盒的市場格局正在經歷變革性變化。次世代定序工作流程正變得更加模組化，使實驗室能夠根據特定的臨床和研究問題客製化定序的深度和廣度。同時，qPCR 化學方法也在不斷多樣化，從而提高了對低拷貝標靶的靈敏度。微陣列平台正擴大被重新用於密集型表達分析和基因分型應用，在這些應用中，成本和周轉時間仍然是至關重要的因素。

對 2025 年推出的新關稅如何重塑實驗室試劑盒供應鏈的韌性、定價策略和產品設計重點進行重點評估。

美國將於2025年對某些實驗室耗材及相關組件加徵關稅，這為受影響的基因組分析試劑盒的製造商、經銷商和最終用戶帶來了新的營運難題。關稅加劇了進口試劑、塑膠製品和儀器耗材的成本壓力，整體採購部門重新評估供應商關係和總到岸成本估算。為此，許多相關人員加快了本地化進程，包括建立區域契約製造夥伴關係，以及尋找化學成分相容且供應鏈檢驗的替代供應商。

詳細的細分分析展示了定序、qPCR、微陣列和雜合反應等子細分領域在技術優先順序、檢驗需求和最終用戶採用模式方面的差異

細分市場趨勢表明，定序、qPCR、微陣列和雜合反應盒的發展軌跡各不相同，技術要求和應用路徑也各有差異。在定序盒方面，次世代定序技術與傳統Sanger定序之間仍存在顯著差異。新一代定序試劑盒涵蓋標靶擴增子panel、EXOME捕獲化學方法和全基因組工作流程，能夠滿足不同的解析度和通量需求；而專注於Sanger定序的毛細管和雙脫氧定序試劑盒仍適用於標靶驗證應用。因此，產品藍圖必須反映通量、準確性和單樣本成本與最終使用者工作流程之間的平衡。

區域比較分析重點闡述了基礎設施、法規和製造能力的差異將如何影響美洲、歐洲、中東和非洲以及亞太地區的試劑盒採用。

區域趨勢對標靶基因組分析試劑盒的應用、監管路徑和採購行為產生了顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現不同的特徵。在美洲，成熟的臨床和研究基礎設施，加上雄厚的公共和私人資金支持，推動了對符合嚴格監管和認證標準的高通量、檢驗試劑盒的需求。因此，供應商能夠受益於當地的監管專業知識和全面的上市後支持，從而維持臨床應用。

策略競爭觀點：產品差異化、供應可靠性與服務生態系統如何決定目標基因組分析試劑盒供應商的領導地位

試劑盒生產商之間的競爭反映了產品創新、供應可靠性和服務生態系統之間的平衡。主要企業透過專有化學技術、整合試劑和儀器產品以及簡化檢測設定和數據解讀的全面軟體支援來脫穎而出。與臨床實驗室和生物製藥公司建立策略聯盟有助於加快檢驗流程並拓展適用範圍，而小規模、專注於特定領域的公司則往往憑藉其專業的化學技術和高度最佳化的單次使用試劑盒而脫穎而出。

旨在增強企業韌性、加速技術採納並在技術、商業性和監管層面建立穩固地位的切實可行的策略建議

產業領導者必須調整策略投資方向，以抓住新機遇，同時管控營運風險。優先考慮供應鏈多元化和區域製造夥伴關係，可降低因貿易中斷和關稅造成的成本波動風險。投資於試劑小型化且可靠的檢驗材料，可降低單次檢測成本，並拓展應用範圍。同時，投資於自動化、使用者友善工作流程和整合分析，有助於在分散式環境和臨床檢查室等需要高度可重複且無誤差流程的場所推廣應用。

我們採用透明的多方法研究途徑，結合一手訪談、技術檢驗和三角驗證的二手證據，以產生可靠的策略見解。

本研究採用多面向方法，整合一手和二手證據，確保研究的嚴謹性和實用性。一級資訊來源包括檢查室主任、採購經理、產品開發人員和法規專家的結構化訪談，並輔以基於已發表最佳實踐的試劑盒性能評估。二手資料包括同行評審文獻、監管文件、專利和供應商技術文檔，以驗證產品功能和以往的應用趨勢。

本文簡要總結了戰略意義，重點闡述了技術、營運和區域因素將如何決定標靶基因組分析試劑盒領域的近期領導地位。

總之，標靶基因組分析試劑盒處於技術、法規和商業實踐的策略交匯點，決定基因體學見解如何轉化為臨床應用和研究突破。定序、qPCR、微陣列和雜合反應化學技術的進步拓展了分析的可能性，而關稅和區域產能缺口導致的供應鏈重組等營運因素則凸顯了穩健的生產製造和適應性商業策略的重要性。總而言之，這些因素有利於那些能夠提供互通性解決方案、檢驗的性能以及完善的售後支援的供應商。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按標靶類型分類的標靶基因組分析試劑盒市場

  • DNA
    • 生殖細胞DNA
    • 體細胞DNA
    • 粒線體DNA
  • RNA
    • mRNA
    • 非編碼RNA
    • 融合轉錄本
  • 表觀遺傳標記
    • DNA甲基化
    • 染色質可及性

第9章 依產品類型分類的標靶基因組分析試劑盒市場

  • 完整套裝
    • 樣品製備工具包
    • 靶向序列捕獲盒
    • 整合圖書館擴充套件
  • 針對特定面板的試劑盒
  • 附件及控制裝置
    • 索引和條碼套件
    • 參考標準和控制
    • 純化和尺寸選擇試劑
  • 軟體和分析軟體包
    • 數據分析軟體許可
    • 解釋和報告工具
    • 基於雲端的分析服務

第10章 依應用分類的標靶基因組分析試劑盒市場

  • 腫瘤學
    • 固態腫瘤學
    • 血液腫瘤科
    • 微量殘存疾病監測
  • 遺傳和罕見疾病
  • 生殖醫學
    • 攜帶者篩檢
    • 產前檢查
    • 胚胎著床前遺傳學檢測
  • 藥物基因組學
  • 感染疾病
    • 病原體鑑定
    • 抗菌藥物抗藥性分析
    • 疫情監測
  • 免疫學與移植
  • 農業和動物健康
  • 消費者基因體學與健康

第11章 以最終用戶分類的標靶基因組分析試劑盒市場

  • 學術研究機構
  • 醫院和臨床檢查室
    • 醫院臨床檢查室
    • 獨立測試機構
  • 製藥和生物技術公司
  • CRO（受託研究機構）
  • 政府與公共衛生研究所
  • 直接面對消費者的檢測公司
  • 工業品管與製造檢查室

第12章 區域性標靶基因組分析試劑盒市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的標靶基因組分析試劑盒市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國標靶基因組分析試劑盒市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國標靶基因組分析試劑盒市場

第16章：中國標靶基因組分析試劑盒市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4F7A6D4FF399

The Targeted Genome Analysis Kits Market was valued at USD 2.89 billion in 2025 and is projected to grow to USD 3.06 billion in 2026, with a CAGR of 6.46%, reaching USD 4.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.89 billion
Estimated Year [2026] USD 3.06 billion
Forecast Year [2032] USD 4.48 billion
CAGR (%) 6.46%

A concise overview of how technological advances, clinical adoption, and supply dynamics are reshaping decision-making around targeted genome analysis kits

Targeted genome analysis kits have moved from niche research tools to foundational elements of translational science, clinical diagnostics, and biopharma development. Advances in assay chemistry, instrument throughput, and bioinformatic interpretation have collectively expanded the utility of sequencing, qPCR, microarray, and hybridization platforms, enabling labs to interrogate genetic variation and expression with greater precision and operational efficiency. As a result, procurement teams, R&D leaders, and diagnostic developers increasingly prioritize kit performance attributes such as sensitivity, specificity, workflow integration, and supply reliability.

Consequently, decision-makers face a complex landscape of technical trade-offs and commercial considerations. Innovation cycles are accelerating, and adoption patterns vary by application area, with oncology, infectious disease surveillance, and rare-disease diagnostics driving demand for higher-resolution assays while routine screening and gene expression studies favor cost-effective, high-throughput solutions. Moreover, regulatory expectations and reimbursement pathways continue to influence which kits move from research use into clinical settings. In light of these dynamics, stakeholders must balance near-term operational needs with longer-term platform investments that support scalability and compliance.

In short, the sector sits at an inflection point where technological maturation meets heightened commercial scrutiny, and strategic clarity is essential for organizations seeking to capture value while managing technical risk and supply complexity.

An analysis of converging technological, logistical, and regulatory forces that are driving rapid shifts in how targeted genome analysis kits are developed, purchased, and deployed

The landscape for targeted genome analysis kits is undergoing transformative shifts driven by parallel advances in instrumentation, reagent chemistry, and data analytics. Next-generation sequencing workflows are becoming increasingly modular, enabling laboratories to tailor depth and breadth of coverage to specific clinical or research questions. At the same time, qPCR chemistries have diversified to deliver enhanced sensitivity for low-copy targets, and microarray platforms are being repurposed for focused expression and genotyping applications where cost and turnaround remain paramount.

Moreover, automation and sample-to-answer integrations are compressing hands-on time and enabling decentralized testing models. This trend intersects with the rise of cloud-enabled bioinformatics and machine learning that streamline variant calling, quality control, and result interpretation. As a result, vendors that provide cohesive kits plus software experiences are gaining traction, whereas suppliers that rely solely on consumable differentiation face margin pressure. Additionally, sustainability considerations and reagent supply-chain resilience have emerged as nontechnical but influential decision criteria, prompting strategic shifts toward local manufacturing and multi-sourcing agreements.

Ultimately, these shifts favor flexible, interoperable solutions that reduce friction from sample to insight, and they reward organizations that couple product innovation with robust support, quality systems, and adaptable commercial models.

A focused evaluation of how new tariff measures introduced in 2025 have reshaped supply chain resilience, pricing strategies, and product design priorities for laboratory kits

The introduction of United States tariffs in 2025 on select laboratory consumables and associated components has introduced a new layer of operational complexity for manufacturers, distributors, and end users of targeted genome analysis kits. Tariffs have amplified cost pressures across imported reagents, plastics, and instrument consumables, prompting procurement teams to reassess supplier relationships and total landed cost assumptions. In response, many stakeholders accelerated localization efforts, ranging from establishing regional contract manufacturing partnerships to qualifying alternate suppliers with compatible chemistries and validated supply chains.

Consequently, pricing dynamics shifted as manufacturers absorbed some cost increases while passing others through in a segmented manner to avoid broad demand disruption. Procurement strategies evolved to emphasize longer-term supply agreements, inventory buffers, and collaborative forecasting to smooth inflows and reduce exposure to tariff volatility. Moreover, the tariffs catalyzed innovation in kit design to reduce reliance on tariffed inputs, including miniaturized reaction volumes, consolidated reagent formulations, and substitution of high-cost components with validated equivalents.

From a strategic perspective, the 2025 tariff environment reinforced the importance of supply chain transparency, cross-border manufacturing flexibility, and contract structures that enable rapid pivoting. For organizations focused on clinical deployment and sustained assay availability, the principal takeaway is that supply resilience and cost management are now integral to product strategy rather than peripheral procurement concerns.

In-depth segmentation insights showing how sequencing, qPCR, microarray, and hybridization subsegments diverge in technical priorities, validation needs, and end-user adoption patterns

Segment-level dynamics reveal differentiated trajectories across sequencing, qPCR, microarray, and hybridization kit types, each with distinct technical requirements and adoption vectors. Within sequencing kits, the broad distinction between next-generation sequencing formats and traditional Sanger methods persists, with next-generation kits spanning targeted amplicon panels, exome capture chemistries, and whole-genome workflows that cater to varying resolution and throughput needs, while Sanger-focused capillary and dideoxy kits remain relevant for targeted confirmatory applications. As a result, product roadmaps must reflect where throughput, accuracy, and cost per sample intersect with end-user workflows.

Turning to qPCR, the dichotomy between dye-based and probe-based systems continues to guide assay selection. Dye-based chemistries, including EvaGreen and SYBR Green derivatives, deliver economical approaches for broad screening and expression analysis, while probe-based formats such as molecular beacons and TaqMan-style assays provide enhanced specificity for diagnostics and multiplexed detection. Buyers therefore evaluate kits not only on sensitivity and dynamic range but also on validation across sample matrices and ease of assay design.

Microarray kits likewise bifurcate into DNA- and RNA-focused formats. DNA microarrays employ comparative genomic hybridization and SNP genotyping arrays that are optimized for structural and variant detection, whereas RNA microarrays emphasize expression profiling and microRNA interrogation for pathway analysis and biomarker discovery. Meanwhile, hybridization kits span fluorescence in situ hybridization products, microchip-based hybridization solutions, and Southern blot reagents; within FISH workflows, direct versus indirect labeling chemistries offer trade-offs between signal intensity and procedural simplicity. Therefore, segmentation insights indicate that customers prioritize kits that align with their analytical goals, validation burden, and throughput constraints, and vendors that offer clear positioning across these subsegments can capture specific application-driven demand.

Comparative regional analysis revealing how differences in infrastructure, regulation, and manufacturing capacity influence kit adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert substantial influence on adoption, regulatory pathways, and procurement behavior for targeted genome analysis kits, with distinct profiles in the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, mature clinical and research infrastructures, coupled with strong private and public funding, drive demand for high-throughput, validated kits that meet stringent regulatory and accreditation standards. Consequently, vendors benefit from local regulatory expertise and comprehensive post-market support to sustain clinical deployments.

In contrast, the Europe, Middle East & Africa region presents a heterogeneous terrain where regulatory harmonization across jurisdictions, diverse reimbursement models, and variable laboratory capacity shape procurement choices. Vendors operating in this region must navigate complex approval processes and adapt commercial models to account for differing adoption speeds and centralized versus decentralized testing strategies. By contrast, the Asia-Pacific region displays rapid capacity expansion, significant investment in domestic manufacturing, and growing clinical adoption across both urban centers and regional hubs; here, cost-efficiency, scalable workflows, and rapid technical support are particularly valued.

Taken together, these regional patterns underscore the need for geographically tailored strategies that combine regulatory navigation, localized supply chain solutions, and market-appropriate commercial models. Transitioning between regions requires calibrated investments in certification, distributor partnerships, and localized technical training to unlock adoption and ensure long-term kit availability.

Strategic competitive perspectives outlining how product differentiation, supply reliability, and service ecosystems determine leadership among targeted genome analysis kit providers

Competitive dynamics among kit manufacturers reflect a balance between product innovation, supply reliability, and service ecosystems. Leading entities differentiate through proprietary chemistries, integrated reagent-instrument offerings, and comprehensive software support that simplifies assay setup and data interpretation. Strategic partnerships with clinical laboratories and biopharma firms accelerate validation pathways and expand addressable use cases, while smaller, niche-focused firms often excel by offering specialized chemistries or highly optimized single-application kits.

In addition, many companies pursue vertical integration to control critical inputs and mitigate supply-chain risk, and they invest in quality management systems and regulatory affairs capabilities to support clinical adoption. Commercial models vary from pure consumable sales to bundled subscription services that include reagents, calibration kits, and remote analytics. Meanwhile, post-sales technical support and training services increasingly determine customer retention as purchasers seek predictable performance in high-stakes clinical and research workflows.

Therefore, competitive advantage increasingly accrues to organizations that combine demonstrable assay performance with resilient manufacturing, proactive regulatory engagement, and a customer-centric service model that reduces adoption friction and supports sustained use.

Actionable strategic recommendations for firms to enhance resilience, accelerate adoption, and build defensible positions across technical, commercial, and regulatory dimensions

Industry leaders must align strategic investments to capture emerging opportunities while managing operational risks. Prioritizing supply chain diversification and regional manufacturing partnerships will reduce exposure to trade disruptions and tariff-induced cost volatility, and investing in reagent miniaturization and robust validation dossiers will lower per-assay costs and expand addressable applications. Parallel investments in automation, user-friendly workflows, and integrated analytics will facilitate adoption in decentralized settings and clinical laboratories that require reproducible, low-error processes.

Furthermore, companies should broaden commercial offerings to include training, assay design support, and lifecycle maintenance services, thereby increasing stickiness and enabling higher lifetime value per customer. Strategic collaborations with clinical networks and academic consortia can accelerate real-world evidence generation and support regulatory submissions. Finally, embedding sustainability considerations into packaging, reagent formulation, and waste management can differentiate offerings for procurement teams increasingly responsible for institutional environmental commitments.

By executing on these priorities, leaders can reduce operational friction for customers, accelerate validation timelines, and position their portfolios to address both high-performance clinical needs and high-volume research demands.

A transparent, multi-method research approach combining primary interviews, technical validation, and triangulated secondary evidence to produce reliable strategic insights

This research synthesizes primary and secondary evidence using a multi-method approach designed to ensure rigor and practical relevance. Primary inputs included structured interviews with laboratory directors, procurement managers, product developers, and regulatory experts, supplemented by technical validation sessions that assessed kit performance attributes against published best practices. Secondary research encompassed peer-reviewed literature, regulatory filings, patents, and vendor technical documentation to triangulate product capabilities and historical adoption trends.

Data synthesis followed a triangulation framework that weighted independent sources to reconcile differences and surface robust insights. Analytical methods included technology readiness assessments, supply-chain mapping, and scenario analysis to understand sensitivity to regulatory shifts and tariff impacts. Quality controls included expert panel reviews and iterative validation with industry practitioners to ensure the report's conclusions aligned with operational realities. Limitations are acknowledged; where public data were sparse-particularly in proprietary contractual terms and confidential product pipelines-the report relied on expert elicitation and validated extrapolations. Nevertheless, the methodology prioritizes transparency and repeatability to support confident decision-making by stakeholders.

A concise synthesis of strategic implications that highlights how technological, operational, and regional forces will determine near-term leadership in targeted genome analysis kits

In conclusion, targeted genome analysis kits occupy a strategic nexus of technology, regulation, and commercial practice that will determine how genomic insights translate into clinical action and research breakthroughs. Technical advances across sequencing, qPCR, microarray, and hybridization chemistries have expanded analytical possibilities, while operational forces-such as tariff-induced supply-chain reshaping and regional capacity differences-have raised the stakes for resilient manufacturing and adaptive commercial strategies. Collectively, these forces favor vendors that deliver interoperable solutions, validated performance, and robust post-market support.

Consequently, organizations that proactively address supply risk, invest in workflow simplification, and align product portfolios with clinical validation imperatives will be best positioned to capture demand across both high-throughput research settings and regulated clinical environments. Looking ahead, disciplined execution across product, supply, and commercial dimensions will separate leaders from followers, and targeted investments in interoperability and customer enablement will accelerate adoption while reducing technical and operational friction.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Genome Analysis Kits Market, by Target Type

  • 8.1. DNA
    • 8.1.1. Germline DNA
    • 8.1.2. Somatic DNA
    • 8.1.3. Mitochondrial DNA
  • 8.2. RNA
    • 8.2.1. mRNA
    • 8.2.2. Non-Coding RNA
    • 8.2.3. Fusion Transcripts
  • 8.3. Epigenetic Marks
    • 8.3.1. DNA Methylation
    • 8.3.2. Chromatin Accessibility

9. Targeted Genome Analysis Kits Market, by Product Type

  • 9.1. Complete Kits
    • 9.1.1. Library Preparation Kits
    • 9.1.2. Target Enrichment Kits
    • 9.1.3. Integrated Library and Enrichment Kits
  • 9.2. Panel-Only Reagent Sets
  • 9.3. Accessories and Controls
    • 9.3.1. Indexing and Barcoding Kits
    • 9.3.2. Reference Standards and Controls
    • 9.3.3. Cleanup and Size Selection Reagents
  • 9.4. Software and Analytics Bundles
    • 9.4.1. Data Analysis Software Licenses
    • 9.4.2. Interpretation and Reporting Tools
    • 9.4.3. Cloud-Based Analysis Services

10. Targeted Genome Analysis Kits Market, by Application Area

  • 10.1. Oncology
    • 10.1.1. Solid Tumor Oncology
    • 10.1.2. Hematologic Oncology
    • 10.1.3. Minimal Residual Disease Monitoring
  • 10.2. Inherited and Rare Disease
  • 10.3. Reproductive Health
    • 10.3.1. Carrier Screening
    • 10.3.2. Prenatal Testing
    • 10.3.3. Preimplantation Genetic Testing
  • 10.4. Pharmacogenomics
  • 10.5. Infectious Disease
    • 10.5.1. Pathogen Identification
    • 10.5.2. Antimicrobial Resistance Profiling
    • 10.5.3. Outbreak Surveillance
  • 10.6. Immunology and Transplantation
  • 10.7. Agriculture and Animal Health
  • 10.8. Consumer Genomics and Wellness

11. Targeted Genome Analysis Kits Market, by End User

  • 11.1. Academic and Research Institutions
  • 11.2. Hospitals and Clinical Laboratories
    • 11.2.1. Hospital-Based Clinical Laboratories
    • 11.2.2. Independent Reference Laboratories
  • 11.3. Pharmaceutical and Biotechnology Companies
  • 11.4. Contract Research Organizations
  • 11.5. Government and Public Health Laboratories
  • 11.6. Direct-To-Consumer Testing Companies
  • 11.7. Industry Quality Control and Manufacturing Laboratories

12. Targeted Genome Analysis Kits Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Targeted Genome Analysis Kits Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Targeted Genome Analysis Kits Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Targeted Genome Analysis Kits Market

16. China Targeted Genome Analysis Kits Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics
  • 17.6. Agilent Technologies, Inc.
  • 17.7. BGI Genomics Co., Ltd.
  • 17.8. Bio-Rad Laboratories
  • 17.9. Eurofins Scientific SE
  • 17.10. F. Hoffmann-La Roche Ltd.
  • 17.11. Illumina, Inc.
  • 17.12. Oxford Nanopore Technologies Ltd.
  • 17.13. Pacific Biosciences of California, Inc.
  • 17.14. PerkinElmer, Inc.
  • 17.15. QIAGEN N.V.
  • 17.16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TARGETED GENOME ANALYSIS KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TARGETED GENOME ANALYSIS KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY GERMLINE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY GERMLINE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY GERMLINE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOMATIC DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOMATIC DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOMATIC DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MITOCHONDRIAL DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MITOCHONDRIAL DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MITOCHONDRIAL DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY NON-CODING RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY NON-CODING RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY NON-CODING RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY FUSION TRANSCRIPTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY FUSION TRANSCRIPTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY FUSION TRANSCRIPTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA METHYLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA METHYLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA METHYLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CHROMATIN ACCESSIBILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CHROMATIN ACCESSIBILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CHROMATIN ACCESSIBILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INTEGRATED LIBRARY AND ENRICHMENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INTEGRATED LIBRARY AND ENRICHMENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INTEGRATED LIBRARY AND ENRICHMENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PANEL-ONLY REAGENT SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PANEL-ONLY REAGENT SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PANEL-ONLY REAGENT SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDEXING AND BARCODING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDEXING AND BARCODING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDEXING AND BARCODING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REFERENCE STANDARDS AND CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REFERENCE STANDARDS AND CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REFERENCE STANDARDS AND CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CLEANUP AND SIZE SELECTION REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CLEANUP AND SIZE SELECTION REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CLEANUP AND SIZE SELECTION REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DATA ANALYSIS SOFTWARE LICENSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DATA ANALYSIS SOFTWARE LICENSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DATA ANALYSIS SOFTWARE LICENSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INTERPRETATION AND REPORTING TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INTERPRETATION AND REPORTING TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INTERPRETATION AND REPORTING TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CLOUD-BASED ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CLOUD-BASED ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CLOUD-BASED ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOLID TUMOR ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOLID TUMOR ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOLID TUMOR ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HEMATOLOGIC ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HEMATOLOGIC ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HEMATOLOGIC ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INHERITED AND RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INHERITED AND RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INHERITED AND RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PATHOGEN IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PATHOGEN IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PATHOGEN IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ANTIMICROBIAL RESISTANCE PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ANTIMICROBIAL RESISTANCE PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ANTIMICROBIAL RESISTANCE PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY OUTBREAK SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY OUTBREAK SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY OUTBREAK SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY IMMUNOLOGY AND TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY IMMUNOLOGY AND TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY IMMUNOLOGY AND TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY AGRICULTURE AND ANIMAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY AGRICULTURE AND ANIMAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY AGRICULTURE AND ANIMAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CONSUMER GENOMICS AND WELLNESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CONSUMER GENOMICS AND WELLNESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CONSUMER GENOMICS AND WELLNESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITAL-BASED CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITAL-BASED CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITAL-BASED CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY GOVERNMENT AND PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY GOVERNMENT AND PUBLIC HEALTH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY GOVERNMENT AND PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DIRECT-TO-CONSUMER TESTING COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDUSTRY QUALITY CONTROL AND MANUFACTURING LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDUSTRY QUALITY CONTROL AND MANUFACTURING LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INDUSTRY QUALITY CONTROL AND MANUFACTURING LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COMPLETE KITS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ACCESSORIES AND CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY SOFTWARE AND ANALYTICS BUNDLES, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY REPRODUCTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY HOSPITALS AND CLINICAL LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY TARGET TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY DNA, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY RNA, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY EPIGENETIC MARKS, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC TARGETED GENOME ANALYSIS KITS MARKET SIZE, BY COM